- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.02. | NICE recommends pharmaand's Rubraca for advanced ovarian cancer | ||
| 25.02. | Recce's topical gel shows promise in acute bacterial skin and skin structure infections | ||
| 25.02. | Porterhouse Medical appoints Michael Tague as president of Porterhouse Medical US | ||
| 25.02. | Class is the missing link in health equity strategies | ||
| 24.02. | PMLiVE's Top Pharma list is live | ||
| 24.02. | Gilead's seladelpar granted conditional EC approval to treat rare liver disease PBC | ||
| 24.02. | Standing out in a crowded precision oncology landscape | ||
| 21.02. | EC approves Biocon's Stelara biosimilar Yesintek for inflammatory diseases | ||
| 21.02. | BMS shares overall survival results for Opdivo in phase 3 lung cancer trial | ||
| 21.02. | Why patients ignore your trials - how to make clinical trials stand out in the real world among the world's biggest brands | ||
| 20.02. | Biogen gains rights to Stoke's Dravet syndrome candidate in deal worth $550m | ||
| 20.02. | FDA grants RMAT designation to AskBio's Parkinson's gene therapy candidate | ||
| 20.02. | EC approves CSL/Arcturus' self-amplifying mRNA COVID-19 vaccine Kostaive | ||
| 20.02. | Inclusivity, collaboration and targeted care | ||
| 19.02. | Merck's Welireg granted EC approval for von Hippel-Lindau disease and kidney cancer | ||
| 19.02. | Sanofi and Regeneron's Dupixent granted FDA priority review for bullous pemphigoid | ||
| 19.02. | AstraZeneca shares promising phase 3 results for Imfinzi in bladder cancer | ||
| 18.02. | EC approves Galderma's Nemluvio to treat atopic dermatitis and prurigo nodularis | ||
| 18.02. | Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis | ||
| 18.02. | FDA approves Bavarian Nordic's chikungunya vaccine for individuals aged from 12 years | ||
| 17.02. | GSK's five-in-one meningococcal vaccine Penmenvy granted FDA approval | ||
| 17.02. | Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer | ||
| 17.02. | Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A | ||
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | ||
| 14.02. | Roche's Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
